Delphi panel reveals how NPs and PAs can talk about long-acting injectables earlier in schizophrenia, boosting adherence and cutting relapse.
Leighann Forbes, PhD
Advertisement
Articles by Leighann Forbes, PhD
Post hoc SUSTAIN-1 data reveal who relapses after stopping intranasal esketamine in TRD—key risk factors guide personalized relapse-prevention plans.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Psychiatric Times
1
Podcast: Practical Insights Into the Evolving Treatment of Bipolar Disorder With David Dunner, MD, FACPsych
2
New Phase 3 Post Hoc Analyses of Centanafadine for the Treatment of Adults With ADHD
3
Celebrating the First APA Panel of Transgender Psychiatrists of Color: A Conversation With Emrys Fonseca, MD, MS
4
Preventing Relapse in Schizophrenia: Focus on Women’s Mental Health
5